ARCT

#3503
Arcturus Therapeutics Holdings Inc. Common Stock
8.63 USD
+2.01%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
8.62
8.69
년간 변동
5.86
24.14
일일 변동
+2.01%
월간 변동
+27.10%
6달 변화
-59.46%
년간 변동율
-16.21%
이전 종가
8.46
Open
8.68
Bid
Ask
Low
8.62
High
8.69
양
56
Open full chart

Financials

Overview 성명 Statistics
Quarterly Annual
  • Market Capitalization 245.29 M
  • Employee 111
  • Founded 2013
  • CEO Joseph E. Payne
  • Website www.arcturusrx.com
  • Headquarter Delaware, United States
  • FIGI BBG00NNW8JK1
  • Industry Technology
총매출
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-2.55
Price to sales ratio
2.05

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025.

뉴스